Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Provista Diagnostics; BG Medicine; and More

Premium

Provista Diagnostics has formed its scientific advisory board, appointing Karen Anderson, Carlos Arteaga, Robert Benezra, Andrew Dannenberg, and Joshua LaBaer.

Anderson is an associate professor at Arizona State University's Biodesign Institute where she specialized in the development of immunodiagnostics and immunotherapies for cancer.

Arteaga is associate director for clinical research and director of the breast cancer program at Vanderbilt-Ingram Cancer Center.

Benezra is an oncologist at Memorial Sloan-Kettering Cancer Center and a professor of biology at Cornell Graduate School of Medical Sciences.

Dannenberg is director of the Weill Cornell Cancer Center, where he focuses on investigating mechanisms underlying the inflammation-cancer connection.

LaBaer is director of ASU's Biodesign Institute and chair of the National Cancer Institute's Early Detection Research Executive Committee and co-chair of its steering committee.


BG Medicine said this week that Bill Densel has joined the company as general manager of its CardioScore business, which offers a diagnostic blood test for identifying individuals at high risk for major near-term cardiovascular events such as heart attack and stroke.

Densel was previously CEO of Dune Medical Devices. Before that he held executive positions at firms including Hologic and Cytyc.


Sera Prognostics has named Sherree Frazier to be vice president of sales and marketing. Frazier will head the company's commercial activities, including development and launch of the ProNid diagnostic test to predict preterm birth risk.

Frazier formerly was senior director of molecular diagnostics and head of North American clinical sales at Qiagen, and prior to that she was women's health manager at Adeza Biomedical, before it was acquired by Cytyc.


Pressure Biosciences has trimmed its board of directors from eight to five, after five of its members resigned and two new members were named to the board.

The resigning directors include Calvin Saravis, Donald Payne, Alan Rosenson, Alan Goldberg, and Gregory Freitag, and the two new members are Vito Mangiardi and Kevin Pollack.

Mangiardi most recently served as COO and deputy director of operations and production for the Joint Genome Institute and has worked for Bio-Rad Laboratories, Baxter Travenol, and Quintiles Transnational, and he was president and CEO of Diagnostics Laboratories. Pollack is managing director at Paragon Capital and is president of Short Hills Capital.


HealthLinx has appointed Vanessa Waddell its new general manager for Australian operations. She will be replacing managing director Nick Gatsios, who stepped down from that role on June 30.

Waddell has consulted with the company on business development and regulatory strategy for the past year. Previously she was CEO of Velacor Therapeutics as well as director of operations and business development intellectual property manager at Prima Biomed Limited.


Bioasis Technologies has appointed Gregory Gubitz to its board of directors.

Gubitz was most recently senior vice president of corporate development and general counsel of Biovail. Before that he was chief operating officer of MDS Capital.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.